Does OBINUTUZUMAB Cause Benign prostatic hyperplasia? 20 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Benign prostatic hyperplasia have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.1% of all adverse event reports for OBINUTUZUMAB.
20
Reports of Benign prostatic hyperplasia with OBINUTUZUMAB
0.1%
of all OBINUTUZUMAB reports
0
Deaths
20
Hospitalizations
How Dangerous Is Benign prostatic hyperplasia From OBINUTUZUMAB?
Of the 20 reports, 20 (100.0%) required hospitalization.
Is Benign prostatic hyperplasia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Benign prostatic hyperplasia?
TADALAFIL (596)
TAMSULOSIN (304)
FINASTERIDE (266)
PANTOPRAZOLE (261)
PREDNISONE (257)
ALBUTEROL (254)
ASPIRIN (243)
TIOTROPIUM (235)
RAMIPRIL (193)
AMLODIPINE (179)
Which OBINUTUZUMAB Alternatives Have Lower Benign prostatic hyperplasia Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE